Drug class in one race
MEK1/2 drugs for Non-Small Cell Lung Cancer
3 tracked MEK1/2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the MEK1/2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 41 Phase 2
Head-to-head evidence: Binimetinib vs Trametinib · Luvometinib vs Trametinib